Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/207684
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Calafat, Margalida | - |
dc.contributor.author | Torres, Paola | - |
dc.contributor.author | Tosca Cuquerella, Joan | - |
dc.contributor.author | Sánchez Aldehuelo, Rubén | - |
dc.contributor.author | Rivero, Montserrat | - |
dc.contributor.author | Iborra, Marisa | - |
dc.contributor.author | González Vivo, María | - |
dc.contributor.author | Vera, Isabel | - |
dc.contributor.author | Castro, Luisa de | - |
dc.contributor.author | Bujanda, Luis | - |
dc.contributor.author | Barreiro de Acosta, Manuel | - |
dc.contributor.author | González Muñoza, Carlos | - |
dc.contributor.author | Calvet, Xavier | - |
dc.contributor.author | Benítez, José Manuel | - |
dc.contributor.author | Llorente Barrio, Mónica | - |
dc.contributor.author | Surís, Gerard | - |
dc.contributor.author | Cañete, Fiorella | - |
dc.contributor.author | Arias García, Lara | - |
dc.contributor.author | Monfort, David | - |
dc.contributor.author | Castaño García, Andrés | - |
dc.contributor.author | Garcia Alonso, Francisco Javier | - |
dc.contributor.author | Huguet, José M. | - |
dc.contributor.author | Marín Jímenez, Ignacio | - |
dc.contributor.author | Lorente, Rufo | - |
dc.contributor.author | Martín Cardona, Albert | - |
dc.contributor.author | Ferrer, Juan Ángel | - |
dc.contributor.author | Camo, Patricia | - |
dc.contributor.author | Gisbert, Javier P. | - |
dc.contributor.author | Pajares, Ramón | - |
dc.contributor.author | Gomollón, Fernando | - |
dc.contributor.author | Castro Poceiro, Jesús | - |
dc.contributor.author | Morales Alvarado, Jair | - |
dc.contributor.author | Llaó, Jordina | - |
dc.contributor.author | Rodríguez, Andrés | - |
dc.contributor.author | Rodríguez, Cristina | - |
dc.contributor.author | Pérez Galindo, Pablo | - |
dc.contributor.author | Navarro, Mercè | - |
dc.contributor.author | Jiménez García, Nuria | - |
dc.contributor.author | Carrillo Palau, Marta | - |
dc.contributor.author | Blázquez Gómez, Isabel | - |
dc.contributor.author | Sesé, Eva | - |
dc.contributor.author | Almela, Pedro | - |
dc.contributor.author | Ramírez de la Piscina, Patricia | - |
dc.contributor.author | Taxonera, Carlos | - |
dc.contributor.author | Rodríguez Lago, Iago | - |
dc.contributor.author | Cabrinety, Lidia | - |
dc.contributor.author | Vela, Milagros | - |
dc.contributor.author | Mínguez, Miguel | - |
dc.contributor.author | Mesonero, Francisco | - |
dc.contributor.author | García, María José | - |
dc.contributor.author | Aguas, Mariam | - |
dc.contributor.author | Márquez, Lucía | - |
dc.contributor.author | Silva Porto, Marisol | - |
dc.contributor.author | Pineda, Juan R. | - |
dc.contributor.author | García Etxebarría, Koldo | - |
dc.contributor.author | Bertoletti, Federico | - |
dc.contributor.author | Brunet, Eduard | - |
dc.contributor.author | Mañosa, Míriam | - |
dc.contributor.author | Domènech, Eugeni | - |
dc.date.accessioned | 2024-02-16T18:08:17Z | - |
dc.date.available | 2024-02-16T18:08:17Z | - |
dc.date.issued | 2024-01-05 | - |
dc.identifier.issn | 1756-2848 | - |
dc.identifier.uri | http://hdl.handle.net/2445/207684 | - |
dc.description.abstract | Infliximab seems to be the most efficacious of the three available anti-TNF agents for ulcerative colitis (UC) but little is known when it is used as the second anti-TNF.Objectives:To compare the clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in UC patients.Design:Retrospective observational study.Methods:Patients from the ENEIDA registry treated consecutively with infliximab and a subcutaneous anti-TNF (or vice versa), naive to other biological agents, were identified and grouped according to the administration route of the first anti-TNF into IVi (intravenous initially) or SCi (subcutaneous initially).Results:Overall, 473 UC patients were included (330 IVi and 143 SCi). Clinical response at week 14 was 42.7% and 48.3% in the IVi and SCi groups (non-statistically significant), respectively. Clinical remission rates at week 52 were 32.8% and 31.4% in the IVi and SCi groups (nonsignificant differences), respectively. A propensity-matched score analysis showed a higher clinical response rate at week 14 in the SCi group and higher treatment persistence in the IVi group. Regarding long-term outcomes, dose escalation and discontinuation due to the primary failure of the first anti-TNF and more severe disease activity at the beginning of the second anti-TNF were inversely associated with clinical remission.Conclusion:The use of a second anti-TNF for UC seems to be reasonable in terms of efficacy, although it is particularly reduced in the case of the primary failure of the first anti-TNF. Whether the second anti-TNF is infliximab or subcutaneous does not seem to affect efficacy. Clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with ulcerative colitis treated with two consecutive anti-TNF agents. Data from the ENEIDA registryBackground: Infliximab seems to be the most efficacious of the three available anti-TNF agents for ulcerative colitis (UC), but little is known when it is used as the second anti-TNF. Objectives: To compare the clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in UC patients. Design: Retrospective observational study. Methods: Patients from the ENEIDA registry treated consecutively with infliximab and a subcutaneous anti-TNF (or vice versa), naive to other biological agents, were identified and grouped according to the administration route of the first anti-TNF into IVi (intravenous initially) or SCi (subcutaneous initially). Results: Overall, 473 UC patients were included (330 IVi, 143 SCi). Clinical response at week 14 was 42.7% and 48.3% in the IVi and SCi groups (non-statistically significant), respectively. Clinical remission rates at week 52 were 32.8% and 31.4%, in the IVi and SCi groups (nonsignificant differences), respectively. A propensity-matched score analysis showed a higher clinical response rate at week 14 in the SCi group and higher treatment persistence in the IVi group. Regarding long-term outcomes, dose escalation and discontinuation due to the primary failure of the first anti-TNF and more severe disease activity at the beginning of the second anti-TNF were inversely associated with clinical remission. Conclusion: The use of a second anti-TNF for UC seems to be reasonable in terms of efficacy, although it is particularly reduced in the case of the primary failure of the first anti-TNF. Whether the second anti-TNF is infliximab or subcutaneous does not seem to affect efficacy. | - |
dc.format.extent | 15 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | SAGE Publications | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1177/17562848231221713 | - |
dc.relation.ispartof | Therapeutic Advances in Gastroenterology, 2024, vol. 17 | - |
dc.relation.uri | https://doi.org/10.1177/17562848231221713 | - |
dc.rights | cc by-nc (c) Calafat, Margalida et al., 2024 | - |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/3.0/es/ | * |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | Colitis ulcerosa | - |
dc.subject.classification | Teràpia intravenosa | - |
dc.subject.other | Ulcerative colitis | - |
dc.subject.other | Intravenous therapy | - |
dc.title | Clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with ulcerative colitis treated with two consecutive anti-TNF agents: data from the ENEIDA registry | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2024-01-29T10:40:20Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 38187926 | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
calafat-et-al-2024-clinical-and-treatment-outcomes-of-a-second-subcutaneous-or-intravenous-anti-tnf-in-patients-with.pdf | 485.15 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License